SEC Form 10-K filed by Avenue Therapeutics Inc.
$ATXI
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
SC 13D/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)
SC 13G - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)
SC 13G/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)
MIAMI, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. ("Urica" or the "Company") (formerly known as UR-1 Therapeutics, Inc.), a Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") subsidiary company focused on the development and commercialization of pharmaceutical products to treat gout and chronic kidney disease, today announced the appointments of Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer and Vibeke Strand, M.D., MACR, FACP, Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University, to its Board of Directors. Lindsay A. Rosenwald, M.D., Fortress' Chairman and Chief Executive Officer and Board Member of Urica, said, "We ar
4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
3 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it will host a virtual key opinion leader ("KOL") event highlighting expert perspectives on spinal bulbar muscular atrophy ("SBMA"), also known as Kennedy's Disease, on Thursday, April 4, 2024 at 11:00am ET. The virtual event will focus on the potential of AJ201 in SBMA, including KOL perspectives on the SBMA treatment landscape, an overview of the Phase 1b/2a study evaluating AJ201 for the treatment of SBMA and outcome co
Total net revenue was $17.4 million in the second quarter of 2023, a 40% increase from $12.4 million in the first quarter of 2023 Positive topline results from two Phase 3 clinical trials evaluating DFD-29 demonstrated achievement of co-primary and all secondary endpoints versus placebo and Oracea® (doxycycline) with no significant safety issues Fortress is advancing several late-stage clinical assets with two NDA submissions anticipated in the second half of 2023 for DFD-29 and CUTX-101 Cosibelimab longer-term results demonstrated substantial increases in complete response rates in advanced cutaneous squamous cell carcinoma PDUFA goal date of January 3, 2024, set by FDA for cosi
SCHEDULE 13D/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)
10-K - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
8-K - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
MIAMI, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the third quarter ended September 30, 2024. "We have generated considerable momentum this past quarter in advancing our pipeline of innovative treatments for neurologic diseases," said Alexandra MacLean, M.D., Chief Executive Officer of Avenue. "AJ201 is a potential best-in-class asset that would bring a disease-modifying therapeutic option to patients with significant unmet m
MIAMI, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in a fireside chat at Maxim Group's 2024 Healthcare Virtual Summit on Tuesday, October 15, 2024 at 1:30 PM ET. The fireside chat will be available to registered attendees. Investors may sign-up or log-in to the conference here. About Avenue TherapeuticsAvenue Therapeutics, Inc. (NASDAQ:ATXI) is a specialty pharmaceutical company focus
MIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in the following upcoming investor conferences: H.C. Wainwright 26th Annual Global Investment ConferenceDate: Monday, September 9, 2024Location: New YorkFormat: Company Presentation and 1x1 Meetings Lake Street Capital Markets BIG8 ConferenceDate: Thursday, September 12, 2024Location: New YorkFormat: 1x1 Meetings The H.C. Wainwright